MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
at-the-market offering, net of...
$52,185K
Proceeds from issuance of
common stock, net of...
$21,483K
Proceeds from issuance of
common stock under...
$344K
Net cash provided by
financing activities
$70,749K
Effect of exchange rate
changes on cash and cash...
$4,091K
Canceled cashflow
$3,263K
Net decrease in
cash, cash...
-$22,470K
Canceled cashflow
$74,840K
Impairment of long-lived
assets
$13,235K
Stock-based compensation
$9,079K
Depreciation and
amortization
$3,961K
Amortization of operating
lease right-of-use...
$3,641K
Accrued compensation
and employee...
$3,053K
Accounts payable and
other accrued...
$2,794K
Prepaid expenses and
other assets
-$830K
Accounts receivable
-$155K
Other
-$32K
Taxes paid related to
net share...
$3,263K
Net cash used in
operating activities
-$97,208K
Canceled cashflow
$36,780K
Net cash (used in)
provided by investing...
-$102K
Net loss
-$122,932K
Deferred revenues
-$6,657K
Lease liabilities
-$4,047K
Other non-current
liabilities
-$352K
Purchases of property and
equipment
$102K
Back
Back
Cash Flow
source: myfinsight.com
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)